NCT06583122 Ultrasound Guided Radiofrequency Ablation of the Occipital Nerve
| NCT ID | NCT06583122 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Kansas Medical Center |
| Condition | Nerve Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2022-07-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Study an ultrasound guided approach to radiofrequency ablation of the occipital nerve that makes it possible to see the needle during treatment procedure. It is hoped this will reduce the amount of pain after the standard of care procedure.
Eligibility Criteria
Inclusion Criteria: * Patients between the ages of 18-80 with a diagnosis of occipital neuralgia or migraine overlying the occipital region. * A diagnosis of occipital neuralgia will be based on the International Classification of Headache Disorders (ICHD), whose criteria include: paroxysmal stabbing pain in the distribution of the GON, tenderness over the affected nerve, and relief of pain for at least 3 hours after bupivacaine local anesthetic block of the affected nerve. * Patients may also be included if they have a diagnosis of migraine based on the ICHD criteria with predominance of pain over the occipital region that responded to occipital nerve block. * Patients must have failed oral medications including NSAIDs, opioids, and anticonvulsants for the management of their pain. * Failed treatment will be \<50% pain reduction with oral medication. * Patients must report headache frequency of at least 10 days per month. Exclusion Criteria: * Patients will be excluded from the trial if they have an unstable medical or psychological condition, * are pregnant, * have an implanted cardiac pacemaker or defibrillator that could not be disabled, * have had a craniotomy or scar tissue overlying the site from a previous surgery, * have a history of cervical spine fusion, * have evidence of elevated ICP or intracranial tumor, * or have previous RFA treatment of the greater or lesser occipital nerve.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06583122 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Nerve Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06583122 currently recruiting?
Yes, NCT06583122 is actively recruiting participants. Contact the research team at tsowder@kumc.edu for enrollment information.
Where is the NCT06583122 trial being conducted?
This trial is being conducted at Kansas City, United States.
Who is sponsoring the NCT06583122 clinical trial?
NCT06583122 is sponsored by University of Kansas Medical Center. The trial plans to enroll 20 participants.